Patent · US Active

CD20-binding polypeptide compositions for treating autoimmune disease

US8337844B2 · kind B2 · utility

18Cited by

1References

19Claims

0Family size

Assignee

Merck Patent GmbH · DE

Inventors

Francis Joseph Carr · Aberdeen, GB
Stephen Williams · Laramie, US
Stephen D. Gillies · Carlisle, US

Key dates

Filing date	Mar 28, 2012
Grant date	Dec 25, 2012
Priority date	—
Expiry date	Mar 28, 2032

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY10S424/801
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A method of treating an autoimmune disease comprising administering to a patient a therapeutically effective amount of a CD20-binding polypeptide composition comprising a combination of a modified heavy chain variable region polypeptide and a modified light chain variable region polypeptide. The combination can be (a) a modified 2B8 antibody heavy chain variable region polypeptide of SEQ ID NO: 48; and a modified 2B8 antibody light chain variable region polypeptide of SEQ ID NO: 49; or (b) a modified Leu16 antibody heavy chain variable region polypeptide of SEQ ID NO: 50; and a modified Leu16 antibody light chain variable region polypeptide of SEQ ID NO: 51.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.